Intravenous Platelet Blockade with Cangrelor during PCI
Deepak L. Bhatt(Mount Sinai Hospital), Robert A. Harrington(Clinical Research Institute), Gilles Montalescot(Maastricht University Medical Centre), Fernando Cura, Derek P. Chew, Kenneth W. Mahaffey(Cardiovascular Institute of the South), Neal S. Kleiman(Houston Methodist), Simona Skerjanec(Doctors Company (United States)), Jaspal Arneja, Gregg W. Stone(Cardiovascular Institute of the South), Shaun G. Goodman(University of Toronto), Charles V. Pollack, Steven E. McNulty, František Toušek(Nemocnice České Budějovice), Harvey D. White(University of Auckland), Ivan H Manukov, M. Zubair Jafar, Steven V. Manoukian, A. Michael Lincoff(Cleveland Clinic), C. Michael Gibson(Baim Institute for Clinical Research), Petr Widimský(Universidad Americana)
Cited by 643
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k